{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:32:49Z","timestamp":1762432369125},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tianjin Key Medical Discipline (Specialty) Construction Project","award":["TJYXZDXK-059B"],"award-info":[{"award-number":["TJYXZDXK-059B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>ACT001 is a novel sesquiterpene lactone derivative that has been shown to have significant antitumor and anti-inflammatory effects. However, the effect of ACT001 on nonalcoholic steatohepatitis (NASH) is unknown. Methionine and choline deficient (MCD) diet induced NASH model in C57BL\/6J mice. Steatosis, inflammation and fibrosis-related indices of serum and liver tissues were detected by fully automated biochemical analyzer, enzyme-linked immunosorbent assay (ELISA) kit, flow cytometry, hematoxylin and eosin (H&amp;E), Masson and immunohistochemical staining. The results showed that ACT001 reduced serum lipid and inflammatory factor levels, attenuated hepatic steatosis, inflammation and fibrosis, and inhibited hepatic oxidative stress and activation of NOD-like receptor protein 3 (NLRP3) inflammatory vesicles in NASH mice. In addition, 381 differentially expressed proteins (DEPs), including 162 up-regulated and 219 down-regulated proteins, were identified in the MCD group and ACT001 high-dose group using isotope labeling relative and absolute quantification (iTRAQ) technique analysis. Among these DEPs, five proteins associated with NAFLD were selected for real-time fluorescence quantitative PCR (RT-qPCR) validation, and the results were consistent with proteomics. In conclusion, ACT001 has a therapeutic effect on NASH, and the results of proteomic analysis will provide new ideas for the mechanism study of ACT001 for NASH treatment.<\/jats:p>","DOI":"10.1038\/s41598-023-38448-4","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T13:02:17Z","timestamp":1689253337000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["iTRAQ-based quantitative proteomics analysis of the effect of ACT001 on non-alcoholic steatohepatitis in mice"],"prefix":"10.1038","volume":"13","author":[{"given":"Hui","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weike","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqiang","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonggang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"38448_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"38448_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"38448_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"38448_CR4","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005\u20132023 (2012).","journal-title":"Hepatology"},{"key":"38448_CR5","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41401-021-00832-z","volume":"43","author":"BE Harvey","year":"2022","unstructured":"Harvey, B. E. NASH: Regulatory considerations for clinical drug development and U.S. FDA approval. Acta Pharmacol. Sin. 43, 1210 (2022).","journal-title":"Acta Pharmacol. Sin."},{"key":"38448_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3389\/fonc.2019.00993","volume":"9","author":"J Guo","year":"2019","unstructured":"Guo, J. et al. Dimethylaminomicheliolide (DMAMCL) suppresses the proliferation of glioblastoma cells via targeting pyruvate kinase 2 (PKM2) and rewiring aerobic glycolysis. Front. Oncol. 9, 993 (2019).","journal-title":"Front. Oncol."},{"key":"38448_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00109-019-01839-0","volume":"98","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. ACT001 modulates the NF-\u03baB\/MnSOD\/ROS axis by targeting IKK\u03b2 to inhibit glioblastoma cell growth. J. Mol. Med. (Berl.) 98, 263\u2013277 (2020).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"38448_CR8","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.7150\/thno.41498","volume":"10","author":"L Tong","year":"2020","unstructured":"Tong, L. et al. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics 10, 5943\u20135956 (2020).","journal-title":"Theranostics"},{"key":"38448_CR9","doi-asserted-by":"publisher","first-page":"112539","DOI":"10.1016\/j.bbr.2020.112539","volume":"383","author":"Q Liu","year":"2020","unstructured":"Liu, Q. et al. Anti-neuroinflammatory effects of dimethylaminomylide (DMAMCL, i.e., ACT001) are associated with attenuating the NLRP3 inflammasome in MPTP-induced Parkinson disease in mice. Behav. Brain Res. 383, 112539 (2020).","journal-title":"Behav. Brain Res."},{"key":"38448_CR10","doi-asserted-by":"publisher","first-page":"8757","DOI":"10.1021\/jm301064b","volume":"55","author":"Q Zhang","year":"2012","unstructured":"Zhang, Q. et al. Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J. Med. Chem. 55, 8757\u20138769 (2012).","journal-title":"J. Med. Chem."},{"key":"38448_CR11","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.18632\/aging.101932","volume":"11","author":"Z Sun","year":"2019","unstructured":"Sun, Z. et al. Long-term every-other-day administration of DMAMCL has little effect on aging and age-associated physiological decline in mice. Aging (Albany NY) 11, 2583\u20132609 (2019).","journal-title":"Aging (Albany NY)"},{"key":"38448_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jchromb.2018.11.004","volume":"1104","author":"X-N Xi","year":"2019","unstructured":"Xi, X.-N. et al. Pharmacokinetics, tissue distribution and excretion of ACT001 in Sprague-Dawley rats and metabolism of ACT001. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1104, 29\u201339 (2019).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"38448_CR13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13046-019-1107-1","volume":"38","author":"N Xu","year":"2019","unstructured":"Xu, N. et al. The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo. J. Exp. Clin. Cancer Res. 38, 118 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"38448_CR14","doi-asserted-by":"publisher","first-page":"65012","DOI":"10.18632\/oncotarget.11342","volume":"7","author":"Q Ji","year":"2016","unstructured":"Ji, Q. et al. Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells. Oncotarget 7, 65012\u201365023 (2016).","journal-title":"Oncotarget"},{"key":"38448_CR15","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1021\/acs.jmedchem.8b00241","volume":"61","author":"J Li","year":"2018","unstructured":"Li, J. et al. Natural product micheliolide (MCL) irreversibly activates pyruvate kinase M2 and suppresses leukemia. J. Med. Chem. 61, 4155\u20134164 (2018).","journal-title":"J. Med. Chem."},{"key":"38448_CR16","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.2147\/CMAR.S244748","volume":"12","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Anticancer effects of ACT001 via NF-\u03baB suppression in murine triple-negative breast cancer cell line 4t1. Cancer Manag. Res. 12, 5131\u20135139 (2020).","journal-title":"Cancer Manag. Res."},{"key":"38448_CR17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/jcb.27146","volume":"120","author":"X-H Jin","year":"2018","unstructured":"Jin, X.-H. et al. ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-\u03baB activation. J. Cell Biochem. 120, 1386\u20131397 (2018).","journal-title":"J. Cell Biochem."},{"key":"38448_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.canlet.2020.04.003","volume":"483","author":"S Yao","year":"2020","unstructured":"Yao, S., Ye, J., Yin, M. & Yu, R. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo. Cancer Lett. 483, 87\u201397 (2020).","journal-title":"Cancer Lett."},{"key":"38448_CR19","doi-asserted-by":"publisher","first-page":"111471","DOI":"10.1016\/j.biopha.2021.111471","volume":"138","author":"J Jaffar","year":"2021","unstructured":"Jaffar, J., Glaspole, I., Symons, K. & Westall, G. Inhibition of NF-\u03baB by ACT001 reduces fibroblast activity in idiopathic pulmonary fibrosis. Biomed. Pharmacother. 138, 111471 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"38448_CR20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41374-019-0245-6","volume":"99","author":"F Peng","year":"2019","unstructured":"Peng, F. et al. Micheliolide ameliorates renal fibrosis by suppressing the Mtdh\/BMP\/MAPK pathway. Lab. Invest. 99, 1092\u20131106 (2019).","journal-title":"Lab. Invest."},{"key":"38448_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00109-019-01757-1","volume":"97","author":"S Li","year":"2019","unstructured":"Li, S. et al. Dimethylaminomicheliolide ameliorates peritoneal fibrosis through the activation of autophagy. J. Mol. Med. (Berl.) 97, 659\u2013674 (2019).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"38448_CR22","first-page":"2325","volume":"8","author":"M Cao","year":"2016","unstructured":"Cao, M. et al. The effect of polyene phosphatidyl choline intervention on nonalcoholic steatohepatitis and related mechanism. Am. J. Transl. Res. 8, 2325\u20132330 (2016).","journal-title":"Am. J. Transl. Res."},{"key":"38448_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1081\/DMR-200033441","volume":"36","author":"CS Lieber","year":"2004","unstructured":"Lieber, C. S. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug. Metab. Rev. 36, 511\u2013529 (2004).","journal-title":"Drug. Metab. Rev."},{"key":"38448_CR24","doi-asserted-by":"publisher","first-page":"e000368","DOI":"10.1136\/bmjgast-2019-000368","volume":"7","author":"IV Maev","year":"2020","unstructured":"Maev, I. V. et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: Real-life observational study from Russia. BMJ Open Gastroenterol. 7, e000368 (2020).","journal-title":"BMJ Open Gastroenterol."},{"key":"38448_CR25","doi-asserted-by":"publisher","first-page":"e000341","DOI":"10.1136\/bmjgast-2019-000341","volume":"7","author":"IV Maev","year":"2020","unstructured":"Maev, I. V. et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol. 7, e000341 (2020).","journal-title":"BMJ Open Gastroenterol."},{"key":"38448_CR26","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52, 1836\u20131846 (2010).","journal-title":"Hepatology"},{"key":"38448_CR27","doi-asserted-by":"publisher","first-page":"20704","DOI":"10.3390\/ijms141020704","volume":"14","author":"A Takaki","year":"2013","unstructured":"Takaki, A., Kawai, D. & Yamamoto, K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int. J. Mol. Sci. 14, 20704\u201320728 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"38448_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan, D., Surabattula, R. & Wang, X. Y. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238\u2013250 (2018).","journal-title":"J. Hepatol."},{"key":"38448_CR29","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037\u20131046 (2017).","journal-title":"J. Hepatol."},{"key":"38448_CR30","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.32320","volume":"76","author":"D Calcagno","year":"2022","unstructured":"Calcagno, D. et al. Nlrp3 activation causes spontaneous inflammation and fibrosis that mimics human NASH. Hepatology 76, 727\u2013741 (2022).","journal-title":"Hepatology"},{"key":"38448_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida, T. & Friedman, S. L. Mechanisms of hepatic stellate cell activation. Nat. Rev. Gastroenterol. Hepatol. 14, 397\u2013411 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"38448_CR32","doi-asserted-by":"publisher","first-page":"154320","DOI":"10.1016\/j.metabol.2020.154320","volume":"111S","author":"N Perakakis","year":"2020","unstructured":"Perakakis, N., Stefanakis, K. & Mantzoros, C. S. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 111S, 154320 (2020).","journal-title":"Metabolism"},{"key":"38448_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fphar.2020.00216","volume":"11","author":"H Xu","year":"2020","unstructured":"Xu, H. et al. Hepatic proteomic changes and Sirt1\/AMPK signaling activation by oxymatrine treatment in rats with non-alcoholic steatosis. Front. Pharmacol. 11, 216 (2020).","journal-title":"Front. Pharmacol."},{"key":"38448_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fphar.2017.00099","volume":"8","author":"F Xia","year":"2017","unstructured":"Xia, F. et al. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic analysis of Hugan Qingzhi and its protective properties against free fatty acid-induced L02 hepatocyte injury. Front. Pharmacol. 8, 99 (2017).","journal-title":"Front. Pharmacol."},{"key":"38448_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jep.2017.09.016","volume":"212","author":"X Yao","year":"2018","unstructured":"Yao, X. et al. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats. J. Ethnopharmacol. 212, 208\u2013215 (2018).","journal-title":"J. Ethnopharmacol."},{"key":"38448_CR36","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","volume":"60","author":"F Tacke","year":"2014","unstructured":"Tacke, F. & Zimmermann, H. W. Macrophage heterogeneity in liver injury and fibrosis. J. Hepatol. 60, 1090\u20131096 (2014).","journal-title":"J. Hepatol."},{"key":"38448_CR37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","volume":"92","author":"A Wree","year":"2014","unstructured":"Wree, A. et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. (Berl.) 92, 1069\u20131082 (2014).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"38448_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jhep.2012.08.018","volume":"58","author":"T-M Leung","year":"2013","unstructured":"Leung, T.-M. & Nieto, N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J. Hepatol. 58, 395\u2013398 (2013).","journal-title":"J. Hepatol."},{"key":"38448_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2008.08.001","volume":"48","author":"G Musso","year":"2009","unstructured":"Musso, G., Gambino, R. & Cassader, M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 48, 1\u201326 (2009).","journal-title":"Prog. Lipid Res."},{"key":"38448_CR40","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.26749","volume":"59","author":"S Sutti","year":"2014","unstructured":"Sutti, S. et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology 59, 886\u2013897 (2014).","journal-title":"Hepatology"},{"key":"38448_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/hep.510270121","volume":"27","author":"MD Weltman","year":"1998","unstructured":"Weltman, M. D., Farrell, G. C., Hall, P., Ingelman-Sundberg, M. & Liddle, C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27, 128\u2013133 (1998).","journal-title":"Hepatology"},{"key":"38448_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12944-015-0124-0","volume":"14","author":"MM Abu-Serie","year":"2015","unstructured":"Abu-Serie, M. M., El-Gamal, B. A., El-Kersh, M. A. & El-Saadani, M. A. Investigation into the antioxidant role of arginine in the treatment and the protection for intralipid-induced non-alcoholic steatohepatitis. Lipids Health Dis. 14, 128 (2015).","journal-title":"Lipids Health Dis."},{"key":"38448_CR43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.apsb.2019.02.006","volume":"9","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Xu, W., Zhai, T., You, J. & Chen, Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm. Sin. B 9, 745\u2013757 (2019).","journal-title":"Acta Pharm. Sin. B"},{"key":"38448_CR44","doi-asserted-by":"publisher","first-page":"G428","DOI":"10.1152\/ajpgi.00217.2019","volume":"318","author":"T Gopal","year":"2020","unstructured":"Gopal, T. et al. Nanoformulated SOD1 ameliorates the combined NASH and alcohol-associated liver disease partly via regulating CYP2E1 expression in adipose tissue and liver. Am. J. Physiol. Gastrointest. Liver Physiol. 318, G428\u2013G438 (2020).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"38448_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0168-8278(02)00073-9","volume":"37","author":"S Seki","year":"2002","unstructured":"Seki, S. et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37, 56\u201362 (2002).","journal-title":"J. Hepatol."},{"key":"38448_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mam.2007.09.016","volume":"29","author":"G Poli","year":"2008","unstructured":"Poli, G., Biasi, F. & Leonarduzzi, G. 4-Hydroxynonenal-protein adducts: A reliable biomarker of lipid oxidation in liver diseases. Mol. Aspects Med. 29, 67\u201371 (2008).","journal-title":"Mol. Aspects Med."},{"key":"38448_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","volume":"8","author":"L Hebbard","year":"2011","unstructured":"Hebbard, L. & George, J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 35\u201344 (2011).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"38448_CR48","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/j.1478-3231.2006.01342.x","volume":"26","author":"M Bilzer","year":"2006","unstructured":"Bilzer, M., Roggel, F. & Gerbes, A. L. Role of Kupffer cells in host defense and liver disease. Liver Int. 26, 1175\u20131186 (2006).","journal-title":"Liver Int."},{"key":"38448_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/joim.12483","volume":"280","author":"J Jager","year":"2016","unstructured":"Jager, J., Aparicio-Vergara, M. & Aouadi, M. Liver innate immune cells and insulin resistance: the multiple facets of Kupffer cells. J. Intern. Med. 280, 209\u2013220 (2016).","journal-title":"J. Intern. Med."},{"key":"38448_CR50","doi-asserted-by":"publisher","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","volume":"302","author":"K Miura","year":"2012","unstructured":"Miura, K., Yang, L., van Rooijen, N., Ohnishi, H. & Seki, E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1310\u2013G1321 (2012).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"38448_CR51","first-page":"135","volume":"38","author":"C Guyot","year":"2006","unstructured":"Guyot, C. et al. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int. J. Biochem. Cell Biol. 38, 135\u2013151 (2006).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"38448_CR52","doi-asserted-by":"publisher","first-page":"13105","DOI":"10.1074\/jbc.270.22.13105","volume":"270","author":"A Colombatti","year":"1995","unstructured":"Colombatti, A., Mucignat, M. T. & Bonaldo, P. Secretion and matrix assembly of recombinant type VI collagen. J. Biol. Chem. 270, 13105\u201313111 (1995).","journal-title":"J. Biol. Chem."},{"key":"38448_CR53","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/hep.32363","volume":"76","author":"M Baptissart","year":"2022","unstructured":"Baptissart, M. et al. Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome. Hepatology 76, 1090\u20131104 (2022).","journal-title":"Hepatology"},{"key":"38448_CR54","doi-asserted-by":"publisher","first-page":"154430","DOI":"10.1016\/j.metabol.2020.154430","volume":"114","author":"J Oh","year":"2021","unstructured":"Oh, J. et al. Type VI collagen and its cleavage product, endotrophin, cooperatively regulate the adipogenic and lipolytic capacity of adipocytes. Metabolism 114, 154430 (2021).","journal-title":"Metabolism"},{"key":"38448_CR55","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/j.1365-2958.1994.tb00384.x","volume":"11","author":"M Herrler","year":"1994","unstructured":"Herrler, M., Bang, H. & Marahiel, M. A. Cloning and characterization of ppiB, a Bacillus subtilis gene which encodes a cyclosporin A-sensitive peptidyl-prolyl cis-trans isomerase. Mol. Microbiol. 11, 1073\u20131083 (1994).","journal-title":"Mol. Microbiol."},{"key":"38448_CR56","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fendo.2017.00360","volume":"8","author":"H Zhang","year":"2017","unstructured":"Zhang, H. et al. Elevated serum cyclophilin B levels are associated with the prevalence and severity of metabolic syndrome. Front. Endocrinol. (Lausanne) 8, 360 (2017).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"38448_CR57","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.3390\/cells10123425","volume":"10","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Giardia duodenalis and its secreted PPIB trigger inflammasome activation and pyroptosis in macrophages through TLR4-induced ROS signaling and A20-mediated NLRP3 deubiquitination. Cells 10, 3425 (2021).","journal-title":"Cells"},{"key":"38448_CR58","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/0008-5472.CAN-16-0357","volume":"77","author":"T Li","year":"2017","unstructured":"Li, T. et al. Gastric cancer cell proliferation and survival is enabled by a cyclophilin B\/STAT3\/miR-520d-5p signaling feedback loop. Cancer Res. 77, 1227\u20131240 (2017).","journal-title":"Cancer Res."},{"key":"38448_CR59","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1194\/jlr.R034025","volume":"54","author":"MC Phillips","year":"2013","unstructured":"Phillips, M. C. New insights into the determination of HDL structure by apolipoproteins: Thematic review series: High density lipoprotein structure, function, and metabolism. J. Lipid Res. 54, 2034\u20132048 (2013).","journal-title":"J. Lipid Res."},{"key":"38448_CR60","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/antiox9111041","volume":"9","author":"LI Elvira-Torales","year":"2020","unstructured":"Elvira-Torales, L. I. et al. Consumption of spinach and tomato modifies lipid metabolism, reducing hepatic steatosis in rats. Antioxidants (Basel) 9, 1041 (2020).","journal-title":"Antioxidants (Basel)"},{"key":"38448_CR61","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cell.2005.08.012","volume":"122","author":"RB Seth","year":"2005","unstructured":"Seth, R. B., Sun, L., Ea, C.-K. & Chen, Z. J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122, 669\u2013682 (2005).","journal-title":"Cell"},{"key":"38448_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/hep.32126","volume":"75","author":"J Fu","year":"2022","unstructured":"Fu, J. et al. A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasis. Hepatology 75, 403\u2013418 (2022).","journal-title":"Hepatology"},{"key":"38448_CR63","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/phar.1194","volume":"33","author":"SC Laizure","year":"2013","unstructured":"Laizure, S. C., Herring, V., Hu, Z., Witbrodt, K. & Parker, R. B. The role of human carboxylesterases in drug metabolism: Have we overlooked their importance?. Pharmacotherapy 33, 210\u2013222 (2013).","journal-title":"Pharmacotherapy"},{"key":"38448_CR64","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.jlr.2021.100075","volume":"62","author":"G Chalhoub","year":"2021","unstructured":"Chalhoub, G. et al. Carboxylesterase 2 proteins are efficient diglyceride and monoglyceride lipases possibly implicated in metabolic disease. J. Lipid Res. 62, 100075 (2021).","journal-title":"J. Lipid Res."},{"key":"38448_CR65","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","volume":"68","author":"PK Santhekadur","year":"2018","unstructured":"Santhekadur, P. K., Kumar, D. P. & Sanyal, A. J. Preclinical models of non-alcoholic fatty liver disease. J. Hepatol. 68, 230\u2013237 (2018).","journal-title":"J. Hepatol."},{"key":"38448_CR66","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jhep.2011.04.010","volume":"55","author":"R Kohli","year":"2011","unstructured":"Kohli, R. & Feldstein, A. E. NASH animal models: Are we there yet?. J. Hepatol. 55, 941\u2013943 (2011).","journal-title":"J. Hepatol."},{"key":"38448_CR67","doi-asserted-by":"publisher","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","volume":"20","author":"Y Takahashi","year":"2014","unstructured":"Takahashi, Y. & Fukusato, T. Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 15539\u201315548 (2014).","journal-title":"World J. Gastroenterol."},{"key":"38448_CR68","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"38448_CR69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: Tool for the unification of biology. the gene ontology consortium. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"38448_CR70","first-page":"111031","volume":"224","author":"SA Aleksander","year":"2023","unstructured":"Aleksander, S. A. et al. The gene ontology knowledgebase in 2023. Genetics 224, 111031 (2023).","journal-title":"Genetics"},{"key":"38448_CR71","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pro.4218","volume":"31","author":"PD Thomas","year":"2022","unstructured":"Thomas, P. D. et al. PANTHER: Making genome-scale phylogenetics accessible to all. Protein Sci. 31, 8\u201322 (2022).","journal-title":"Protein Sci."},{"key":"38448_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"38448_CR73","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"38448_CR74","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38448-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38448-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38448-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T14:08:08Z","timestamp":1689257288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38448-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38448"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38448-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11336"}}